Project Grant R43DA060726
Award Date
6/1/24
Completion Date
5/31/25
Dollars Obligated
$295K
Federal Agency
National Institute on Drug Abuse
Awardee
Epivario Inc. (M6ZTFQ3K1WT3)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $275,253 to Epivario Inc. for the period of September 30, 2024 to September 29, 2025. The funding will support research and development efforts to identify a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). Epivario, a biotechnology research company, will screen next-generation inhibitors of the metabolic...
This $492,000 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports cutting-edge research to elucidate the genetic and epigenetic factors governing cocaine addiction. The University of Chicago, the prime awardee, will employ a multidimensional approach involving genomics, epigenomics, neuroscience, and computational biology. The key objectives include: 1) Profiling cell-type and circuit-specific...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services (DHHS), supports research to develop a novel therapeutic target for cocaine use disorder. The funding of $405,230 will be used by Rafias LLC, a for-profit, woman-owned small business, to conduct lead identification and optimization studies on activating the NR4A1 nuclear receptor as a potential treatment for cocaine addiction. The research aims to identify a...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $249,236 to Duke University to investigate the role of chromatin regulation and the expression of the brain-derived neurotrophic factor (BDNF) gene in driving persistent drug-seeking behaviors associated with cocaine addiction.
The project will use innovative molecular genetic techniques to define changes in the chromatin architecture...
This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $180,646 to investigate the molecular mechanisms by which astrocytes, a type of brain cell, regulate cocaine addiction-related behaviors. The primary awardee, the Icahn School of Medicine at Mount Sinai, will conduct the research under the mentorship of Drs. Eric Nestler, Paul Kenny, and Li Shen. The project aims to elucidate the...
The National Institute on Drug Abuse (NIDA) awarded Vanderbilt University a $149,284 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 26, 2024. The grant aims to define how chronic cocaine use disrupts the brain's dopaminergic system and its ability to process aversive stimuli. Specifically, the project will use single-cell calcium imaging and optogenetic manipulation in behaving animals to establish the temporal conditions under which dopamine...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $454,470 to Drexel University to develop a new imaging pipeline that examines epigenetic spatial architecture in the central nervous system (CNS) of mice with HIV infection that self-administer cocaine. The goal is to understand the mechanisms by which altered histone dopaminylation in astrocytes may contribute to increased sensitivity to...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $158,024 to the University of California, Irvine to investigate the role of the gene GILZ in regulating cocaine-induced cellular activity and cocaine-associated memory formation. The research aims to determine if GILZ, an X-linked gene, mediates sex-dependent transcriptional changes underlying reward-associated behaviors in response to...
This $445,500 Project Grant award, funded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs), will support research at the University of Alabama at Birmingham (UAB) to identify and characterize conserved genetic regulators of drug-induced plasticity in the Caenorhabditis elegans nervous system. The project aims to generate comprehensive molecular, behavioral, and neuronal activity atlases in response to acute and chronic cocaine exposure in this...